Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

CVAC vs BGM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CVAC Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

CVAC Overall Winner 6-Pillar Tally: CVAC 4 – 1 BGM (1 Tie) Matrix Metrics: CVAC 8 – 2 BGM

As of Nov 19, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVAC carries a Unified Composite Score of 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin), whereas BGM carries 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin).

  • Growth vs. Quality Trade-Off: CVAC earns the overall head-to-head edge with a stronger Unified Composite Score (60.2/100 BUY vs. BGM 59.6/100 HOLD) and 1.20β · 62% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVAC vs BGM
CVAC NASDAQ Head-to-Head Winner
CureVac N.V. Ordinary Shares
Pharmaceutical Preparations
$4.66
-0.21% 1D
Market Cap $1.1B
TTM Revenue $71M
Forward P/E 5.2x
Beta / 30D Vol 1.20β · 62% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.9 · SMA20: $4.64 · SMA50: $5.02
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25

6-Pillar Scorecard Institutional Category Breakdown (CVAC 4 – 1 BGM)

Columns: Metric · CVAC · BGM
1. Valuation Multiples CVAC
Forward P/E 5.2x N/M
Trailing P/E 7.0x N/M
PEG Ratio N/M N/M
EV / Revenue 14.9x 2.3x
2. Growth & Scale CVAC
Revenue Growth (YoY) -89.0% +69.8%
Earnings Growth (YoY) +24.0% +0.0%
TTM Revenue (USD) $71M $48M
Market Cap $1.1B $108.6M
3. Profitability & Quality CVAC
Gross Margin 93.3% 16.9%
Operating Margin 573.0% -23.4%
Net Profit Margin 182.1% -44.2%
Return on Equity (ROE) 40.2% -7.4%
4. Balance Sheet & Cash Flow CVAC
Cash Generation (TTM) $194M EBITDA -$9.2M EBITDA
Cash Flow Margin N/A -19.3% EBITDA Mgn
Net Cash / Leverage $5.65 Book/Sh · 40.2% ROE $59.55 Book/Sh · -7.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 63.4% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat BGM
OpEx & R&D Intensity N/A 40.3% of Rev ($19M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVAC (8) vs BGM (2)
Institutional Metric CVAC BGM Criterion Row Edge
Market Capitalization
Scale
$1.1B $108.6M Larger Scale CVAC
Trailing P/E Ratio
Valuation
7.0x N/M Lower Multiple CVAC
Forward P/E Ratio
Valuation
5.2x N/M Lower Multiple CVAC
Revenue Growth (YoY)
Growth
-89.0% +69.8% Higher Growth BGM
Operating Margin (TTM)
Profitability
573.0% -23.4% Higher Margin CVAC
Net Profit Margin
Profitability
182.1% -44.2% Higher Margin CVAC
Return on Equity (ROE)
Capital Efficiency
40.2% -7.4% Higher ROE CVAC
52-Week Range Position
Momentum
67% ($2–$6) 74% ($0–$11) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
1.20β · 62% Vol 3.69β · 80% Vol Lower Realized Risk CVAC
Unified Institutional Score
Composite Signal
60.2 / 100 (BUY) 59.6 / 100 (HOLD) Higher Composite CVAC
Trailing 12M Revenue (USD)
Operating Scale
$71M $48M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.3% 16.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.9x EV/Rev N/M PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$194M EBITDA ($5.65 Book/Sh · 40.2% ROE) -$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVAC +43.88 pp
CVAC: -9.95% · BGM: -53.83%
3M Horizon CVAC +53.56 pp
CVAC: -10.56% · BGM: -64.12%
6M Horizon CVAC +53.56 pp
CVAC: -10.56% · BGM: -64.12%
1Y Horizon CVAC +53.56 pp
CVAC: -10.56% · BGM: -64.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CVAC vs BGM. Trailing 12-month operating profitability (CVAC 573.0% vs BGM -23.4%) and valuation multiples (CVAC 5.2x vs BGM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CVAC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$71M
Gross Margin93.3%
Op. Margin573.0%
ROE / Fwd P/E40.2% · 5.2x
BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVAC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 63.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVAC Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 573.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published

Investor FAQ CVAC vs BGM Key Questions & Quantitative Answers

As of Nov 19, 2026, CureVac N.V. (CVAC) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CVAC carries a Unified Composite Score of 60.2/100 (BUY) at $4.66 (5.2x Forward P/E, 573.0% operating margin), whereas BGM carries 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin). Growth vs. Quality Trade-Off: CVAC earns the overall head-to-head edge with a stronger Unified Composite Score (60.2/100 BUY vs. BGM 59.6/100 HOLD) and 1.20β · 62% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

CVAC leads the Growth & Scale pillar: CVAC posts -89.0% YoY revenue growth and +24.0% YoY earnings growth on $71M TTM revenue (93.3% gross margin, 573.0% operating margin), compared with BGM at +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin). On trailing 12-month operating scale, CVAC generates $71M in USD-normalized revenue versus $48M for BGM. In operating R&D and SG&A reinvestment, CVAC deploys N/A (0 90-day corporate R&D disclosures) versus 40.3% of Rev ($19M) (0 disclosures) for BGM.

CVAC screens cheaper on headline valuation multiples. CVAC trades at 5.2x Forward P/E, 7.0x Trailing P/E, N/M PEG, and 14.9x EV/Revenue (unreported EBITDA margin), whereas BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVAC (40.2% ROE) versus BGM (-7.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CVAC carries 63.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.20β · 62% Vol realized risk). By comparison, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.